{"id":9479,"date":"2015-12-11T17:07:03","date_gmt":"2015-12-11T20:07:03","guid":{"rendered":"http:\/\/www.amchamchile.cl\/?p=146145"},"modified":"2015-12-11T17:07:27","modified_gmt":"2015-12-11T20:07:27","slug":"industria-biotecnologica-toma-forma-en-chile","status":"publish","type":"news","link":"https:\/\/amchamchile.cl\/en\/noticia\/industria-biotecnologica-toma-forma-en-chile\/","title":{"rendered":"[:es]Industria biotecnol\u00f3gica toma forma en Chile[:en]Biotechnology industry takes shape in Chile[:]"},"content":{"rendered":"

[:es]Desde Corfo est\u00e1n impulsando la creaci\u00f3n de una Plataforma que d\u00e9 un norte estrat\u00e9gico al sector y agrupe de forma ordenada todas las iniciativas que hoy se est\u00e1n llevando a cabo de forma aislada.<\/em><\/p>\n

Por Alejandra Maturana\u00a0<\/strong><\/p>\n

\u201cNo s\u00f3lo queremos desarrollar con la biotecnolog\u00eda nuestras industrias basadas en recursos naturales, sino que tambi\u00e9n crear industrias complementarias asociadas a mayor cantidad de empresas de servicios y conocimiento. Queremos rentabilizar la inversi\u00f3n p\u00fablica que se ha hecho en los \u00faltimos diez a\u00f1os en nuestro sistema de innovaci\u00f3n, sacar eso de los anaqueles de la ciencia y transportarlo a su aplicaci\u00f3n industrial\u201d. Con dicha frase el pasado 16 de noviembre la Subsecretaria de Econom\u00eda, Katia Trusich, abr\u00eda la Biolatam 2015, la feria de biotecnolog\u00eda m\u00e1s importante de la regi\u00f3n que se realizaba por primera vez en territorio nacional.<\/p>\n

La elecci\u00f3n de Chile \u00a0como pa\u00eds anfitri\u00f3n de este evento no fue al azar. Nombres como el del reconocido bioqu\u00edmico Pablo Valenzuela ya lo hab\u00edan hecho sonar en la palestra del sector a nivel mundial tras su exitosa participaci\u00f3n en la creaci\u00f3n de la vacuna contra el virus de la hepatitis B, a la que le siguieron otra serie de investigaciones y descubrimientos en el campo de la ciencia. El tambi\u00e9n empresario hoy es un referente en el \u00e1mbito de la biotecnolog\u00eda gracias a la presencia de su marca sectorial ChileBiotech en diferentes ferias y eventos alrededor del globo.<\/p>\n

Sin embargo, a pesar de su gran potencial, el pa\u00eds sigue presentando desaf\u00edos para el desarrollo de la biotecnolog\u00eda. Por eso, desde Corfo est\u00e1n trabajando en la creaci\u00f3n de una Plataforma Biotecnol\u00f3gica que d\u00e9 un norte estrat\u00e9gico a la industria, cuya hoja de ruta comenzar\u00e1 a construirse en 2016 y estar\u00e1 a cargo del cient\u00edfico chileno y acad\u00e9mico de la Universidad de Arizona, Fernando Mart\u00ednez.<\/p>\n

\u201cLa biotecnolog\u00eda puede tener un impacto importante en la diversificaci\u00f3n y sofisticaci\u00f3n de la miner\u00eda, salmonicultura, fruticultura y forestal, que son los sectores exportadores m\u00e1s grandes de Chile. Tambi\u00e9n podemos desarrollar la biomedicina, aprovechando que m\u00e1s de\u00a0 25% de la investigaci\u00f3n b\u00e1sica que se realiza en el pa\u00eds responde a ese campo\u201d, se\u00f1ala el vicepresidente ejecutivo de Corfo, Eduardo Bitran.<\/p>\n

Apunta que se trata de un \u00e1mbito que no es espec\u00edfico del pa\u00eds y que es altamente competitivo a nivel mundial, pues es justamente donde grandes jugadores como Estados Unidos e Inglaterra est\u00e1n concentrando sus inversiones. Por eso, se\u00f1ala, s\u00f3lo pocos grupos de excelencia con claras posibilidades de hacer contribuciones reales ser\u00e1n apoyados. \u201cUn ejemplo concreto es el proyecto sobre el c\u00e1ncer de Ciencias Para la Vida de Pablo Valenzuela, que es el m\u00e1s avanzado y con mayor potencial a nivel global\u201d, ejemplifica.<\/p>\n

El surgimiento de la plataforma<\/strong><\/p>\n

Desde inicios del a\u00f1o 2000, Corfo y la Comisi\u00f3n Nacional de investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica (Conicyt) han entregado fondos para diversos proyectos biotecnol\u00f3gicos, entre ellos, el mejoramiento gen\u00e9tico y de condiciones de postcosecha de distintas variedades frutales y hort\u00edcolas, la creaci\u00f3n de vacunas para salmones, el desarrollo de tecnolog\u00eda clonal para especies forestales, la obtenci\u00f3n de biocombustible a partir de microalgas y el proyecto que en 2002 dio origen a BioSigma (firma biotecnol\u00f3gica enfocada en procesos mineros ligada a Codelco).<\/p>\n

Asimismo, Corfo apoy\u00f3 el surgimiento de dos fondos de capital de riesgo especializados (Aurus Bios y Austral Capital) con cerca de US$32 millones, el aterrizaje en Chile de los centros internacionales de Pfizer y Fraunhofer, y las operaciones de la incubadora Austral Incuba y el espacio de cowork<\/em> Santiago Lab Space, adem\u00e1s de UDD Ventures e Incuba UC, que si bien no s\u00f3lo atienden a startups<\/em> vinculadas a este sector, tienen una fuerte inclinaci\u00f3n hacia \u00e9l. Incluso, el programa Start-Up Chile ha presentado \u00faltimamente especial inter\u00e9s por los desarrollos biotecnol\u00f3gicos, y ya ha apoyado a 58 emprendimientos de este tipo con m\u00e1s de $ 1.120 millones.<\/p>\n

Sin embargo, como se\u00f1ala el presidente del directorio cient\u00edfico de la futura Plataforma Biotecnol\u00f3gica, Fernando Mart\u00ednez, todos estos no son m\u00e1s que proyectos dispersos sin un norte estrat\u00e9gico.<\/p>\n

\u201cDe la primera cosa que me di cuenta volviendo a Chile es que aunque existen muchas iniciativas, no hay una idea clara de qu\u00e9 es lo que hay, cu\u00e1l es el valor que tiene, cu\u00e1les son sus objetivos, ni con qui\u00e9n est\u00e1n colaborando. Por eso, lo primero que haremos ser\u00e1 una evaluaci\u00f3n para saber exactamente con qu\u00e9 capacidades contamos para el desarrollo de biotecnolog\u00eda aplicada, y a partir de eso dise\u00f1ar un plan estrat\u00e9gico que considere los recursos humanos y tecnol\u00f3gicos existentes\u201d, indica.<\/p>\n

Una vez obtenida esta informaci\u00f3n, se definir\u00e1n ciertas \u00e1reas de prioridad estrat\u00e9gica, dos o tres seg\u00fan estima Mart\u00ednez, pues hay que entender que la biotecnolog\u00eda no puede ser tratada de manera dispersa, sino que debe ser concentrada. A ello se suma que el pa\u00eds no cuenta con los recursos econ\u00f3micos para desarrollarla estrat\u00e9gicamente sobre todos sus sectores productivos.<\/p>\n

\u201cTodo lo que existe en Chile como modelo de desarrollo de la bioindustria es \u00b4federado\u00b4, es decir, el Estado pregunta a cient\u00edficos y empresas en qu\u00e9 invertir, y en base a criterios de concurso que se sustentan en la calidad relativa de este tipo de propuestas, se destinan los recursos. Por eso, todo lo que se hace es muy disperso y a peque\u00f1a escala, lo que es letal en la biotecnolog\u00eda, pues necesita todo lo contrario\u201d, sostiene.<\/p>\n

\"777777777777\"<\/p>\n

EE.UU. como modelo y aliado<\/strong><\/p>\n

Cuando se habla de biomedicina es casi imposible no pensar en Boston, Estados Unidos. En esta ciudad, desde 1980, el sector comenz\u00f3 a desarrollarse con especial fuerza de la mano de esfuerzos p\u00fablicos y privados, pero tambi\u00e9n desde la filantrop\u00eda. De hecho, el s\u00faper cl\u00faster<\/em> de ciencias de la vida de Massachusetts cuenta con 122 universidades, 400 firmas de tecnolog\u00eda m\u00e9dica, 550 compa\u00f1\u00edas de biofarma, 6 de los mejores diez hospitales de investigaci\u00f3n y ocupa el primer lugar de fondos de capital de riesgo per c\u00e1pita en Estados Unidos, en la atracci\u00f3n de fondos federales de investigaci\u00f3n y en nivel educacional de la fuerza de trabajo, adem\u00e1s de la mayor concentraci\u00f3n de spin out<\/em> per c\u00e1pita nacidos en instituciones de investigaci\u00f3n.<\/p>\n

\"yyukyuklyuklujlhju\"<\/p>\n

As\u00ed lo explica Lorena Palomo, chief operating officer de la C\u00e1mara Chileno Norteamericana de Comercio, AmCham Chile, quien en octubre lider\u00f3 la Misi\u00f3n Biotecnol\u00f3gica en el Sector Salud: Una Mirada en 360\u00b0, realizada en el marco de la alianza entre Chile y el estado de Massachusetts, y que tambi\u00e9n cont\u00f3 con colaboraci\u00f3n de la Embajada de Chile en Estados Unidos, Corfo y Pfizer, adem\u00e1s del auspicio de Fundaci\u00f3n Imagen de Chile.<\/p>\n

\u201cVisitamos distintos lugares en Washington D.C. y Boston, con un equipo de lo m\u00e1s variado en el que participaron investigadores, acad\u00e9micos y representantes del \u00e1mbito p\u00fablico-privado, los que conocieron distintos modelos de trabajo en el \u00e1rea de la biomedicina\u201d, cuenta la ejecutiva, se\u00f1alando que la experiencia buscaba mostrar el funcionamiento del ecosistema biotecnol\u00f3gico estadounidense in situ y con fuentes directas tanto en temas de financiamiento, modelos de trabajo, transferencia tecnol\u00f3gica y de propiedad intelectual.<\/p>\n

En esa l\u00ednea, la ejecutiva destac\u00f3 que la misi\u00f3n no s\u00f3lo sirvi\u00f3 para que los asistentes aprendieran del caso de \u00e9xito del cl\u00faster biotecnol\u00f3gico de Massachusetts, sino que para que tambi\u00e9n visualizaran experiencias replicables en Chile y nuevas formas de cooperaci\u00f3n. \u201cPor ejemplo, el equipo pudo conocer distintas capacidades y servicios, y darse cuenta de que no estamos tan lejanos a la experiencia de Boston en cuanto al coworking. Un ejemplo de ello es el trabajo liderado por Santiago LabSpace\u201d, explica.<\/p>\n

\"yyrtyrtyrt\"<\/p>\n

El director ejecutivo de LabSpace, Ignacio Brescia, fue uno de los integrantes de la misi\u00f3n de AmCham. Durante su estad\u00eda en Estados Unidos pudo constatar la estructura del \u00e1mbito biotecnol\u00f3gico en dicho pa\u00eds: \u201cMe pareci\u00f3 sumamente interesante que all\u00e1 todo ocurre centralizadamente. El MIT, Pfizer, Novartis, Janssen, universidades, empresas, centros de investigaci\u00f3n, inversionistas\u2026 todo est\u00e1 en un mismo lugar y eso agiliza mucho los procesos. De hecho, basta con que un cient\u00edfico llame por celular a un inversionista para que en cinco minutos est\u00e9n ambos hablando de negocios en el Starbucks que queda cruzando la calle, y no con la disposici\u00f3n que hay ac\u00e1, para nada, sino que con un `\u00a1hag\u00e1moslo ya!`\u201d.<\/p>\n

Para el ejecutivo, aprender del modelo estadounidense y saber aprovechar sus capacidades presenta una gran oportunidad para Chile y sus empresas enfocadas en ciencias de la vida. De hecho, sin ir m\u00e1s all\u00e1, adelanta que ellos mismos est\u00e1n constituyendo una nueva empresa (Research to Business Catalyst-R2B Catalyst) con el centro de excelencia de la Universidad de California, UC Davis Chile.<\/p>\n

\u201cChile cuenta con cient\u00edficos y emprendedores con mucha visi\u00f3n para resolver problem\u00e1ticas, y queremos aprovechar su gran conocimiento tratando de facilitarles el camino para el desarrollo de una nueva tecnolog\u00eda\u201d, apunta Pablo Zamora, director cient\u00edfico de UC Davis Chile. Es as\u00ed que R2B Catalyst contar\u00e1 con dos tipos de infraestructura: sus laboratorios del centro UC Davis LabSpace en Providencia para desarrollos de biolog\u00eda celular, molecular o microbiolog\u00eda, y el Patagonia LabSpace de Puerto Montt para quienes est\u00e1n en proceso de escalamiento o desarrollo de prototipado; y, adicionalmente, las startups<\/em> apoyadas podr\u00e1n acceder a todo el conocimiento y las redes de la Universidad de California, aumentando sus posibilidades de llegar al mercado exitosamente.<\/p>\n

\u201cChile tiene bastantes posibilidades en el campo de la biotecnolog\u00eda. Sin embargo, mientras no exista una visi\u00f3n de querer estar en la frontera del desarrollo de la innovaci\u00f3n, s\u00f3lo seremos un veh\u00edculo para levantar recursos y luego esas tecnolog\u00edas partir\u00e1n a otros lados para sus mejoras productivas\u201d, enfatiza.<\/p>\n

Si bien la biotecnolog\u00eda ha dado pasos importantes desde hace al menos una d\u00e9cada, habr\u00e1 que esperar el pr\u00f3ximo a\u00f1o para conocer la hoja de ruta que trazar\u00e1 Corfo para estimar el potencial de una industria que cada vez tiene m\u00e1s proyectos, pero que por ahora requiere mayores recursos e investigadores dedicados al desarrollo de este \u00e1mbito en Chile.[:en]Corfo is driving the creation of a platform that will help devise a strategic roadmap for the sector and centralize all initiatives currently pursued on an isolated basis<\/em><\/p>\n

By Alejandra Maturana<\/strong><\/p>\n

\u201cNot only do we wish to develop our natural resource-based industries with biotechnology, but also to develop complementary industries associated with an increased number of service companies and additional expertise. We want to secure the maximum return on the public investment made in our innovation system over the last decade, removing it from the scientific side and giving it an industrial application\u201d. With these words, on 16 November 2015, Katia Trusich, Undersecretary of Economy, opened Biolatam, the most important biotechnology conference in the region, which, for the first time, was held in Chile.<\/p>\n

The choice of Chile as host of the conference was not by chance. Individuals, such as renowned biochemist Pablo Valenzuela, had already made themselves known in the sector on the global level. In the case of Valenzuela, his recognition comes from his successful participation in developing the vaccine against the Hepatitis B virus, followed by a further series of investigations and discoveries in the field of science. Valenzuela, who is also a businessman, is a leading figure in the field of biotechnology, thanks to the solid positioning of his ChileBiotech brand in different fairs and events around the world.<\/p>\n

Nevertheless, and despite its huge potential, Chile still faces certain challenges in terms of biotechnology development. That is why Corfo, the Chilean economic development agency, is currently creating a biotechnology platform that will help devise a strategic roadmap for the sector. It will begin to take shape in 2016, under the charge of Chilean scientist and academic from the University of Arizona, Fernando Mart\u00ednez.<\/p>\n

\u201cBiotechnology can have a significant impact on the diversification and sophistication of the mining, salmon aquaculture, fruit farming and forestry sectors, which represent the largest export sectors in Chile. We can also develop biomedicine, by taking advantage of more than 25% of the basic research undertaken in the country in this field\u201d, says Eduardo Bitran, executive vice president of Corfo.<\/p>\n

Bitran points out that this is not an area specific to Chile and that it is a highly competitive sector at the global level; one on which large players like the United States and the United Kingdom are concentrating their investments. Accordingly, Bitran states that only a select few groups of excellence with clear possibilities of making genuine contributions will be supported: \u201cone concrete example is Pablo Valenzuela\u2019s Ciencia Para la Vida cancer project, which is one of the most advanced and potentially beneficial in the world\u201d.<\/p>\n

The growth of the platform<\/strong><\/p>\n

Since the beginning of the 2000s, Corfo and the National Commission for Scientific and Technological Research (Conicyt) have provided funding for a number of different biotechnology projects. These include the improvement and genetic enhancement of the postharvest conditions of different fruit and vegetable varieties; the creation of vaccines for salmon; the development of clone technology for forestry species; obtaining biofuel from microalgae; and the project which, in 2002, led to the creation of BioStigma, the biotechnology firm specializing in mining processes and which is associated to Codelco, the Chilean national copper corporation.<\/p>\n

Likewise, Corfo has sponsored a number of additional projects, including: the emergence of two specialist venture capital funds (Aurus Bios and Austral Capital), with almost US$32 million; the arrival in Chile of the international centers of Pfizer and Fraunhofer; the business incubator Austral Incuba, in the co-work space of Santiago Lab Space; and, similarly, UDD Ventures, from the Universidad de Desarrollo, and Incuba UC, from the Pontificia Universidad Cat\u00f3lica de Chile, which, despite neither working exclusively with start-ups in the industry, are both strongly linked to the area. Moreover, the Start-Up Chile program has recently shown growing interest in biotechnology developments, having already sponsored 58 business ventures of this type with more than US$1.12 billion.<\/p>\n

However, as Fernando Mart\u00ednez, the chairman of the scientific board of the future biotechnology platform, says, these projects are nothing more than a scattered group if they lack a strategic focus.<\/p>\n

He recalls that, \u201cone of the first things I noticed on my return to Chile was that, despite the number of initiatives, there is no clear idea of what exactly is available, what value there is, what the strategic objectives are, or with whom these projects are collaborating. That\u2019s why the first thing we\u2019ll do is conduct a thorough evaluation, to gauge exactly what abilities we have for developing applied biotechnology, and from there, design a strategic plan which includes the human and technological resources available\u201d.<\/p>\n

Once this information has been gathered, certain areas of strategic priority will be defined; two or three, according to Mart\u00ednez. He stresses the importance of addressing biotechnology in a centralized manner, rather than, as it is at present, on a dispersed basis. He also claims that Chile is lacking in financial resources to develop the area strategically across all productive levels.<\/p>\n

\u201cEverything that exists in Chile as a development model for the bioindustry is \u201cfederalized\u201d, i.e., the State asks scientists and businesses in what to invest, and, based on the tender criteria determined by the relative quality of these types of projects, resources are allocated. That\u2019s why everything that happens is so scattered and on such a small scale, which is lethal in biotechnology, which needs precisely the opposite (approach)\u201d, he explains.<\/p>\n

\"777777777777\"<\/p>\n

The United States as both model and ally<\/strong><\/p>\n

When reference is made to biomedicine, it is almost impossible not to recall Boston, in the United States. Since 1980, the city has overseen the development of the sector, with particular assistance from public and private initiatives, as well as philanthropy. In fact, the super-cluster of life sciences at Massachusetts includes: 122 universities, 400 medical technology firms; 550 biofarming companies; six of the nation\u2019s best ten research hospitals; and first place on the list of venture capital funds per capita in the country, in terms of attracting federal research funding, as well as first position regarding the overall educational level of the workforce. It also has the greatest per capita concentration of spin-out companies from new research institutions.<\/p>\n

 <\/p>\n

Palomo notes: \u201cWe visited different places in Washington D.C. and Boston with a mixed team composed of researchers, academics and representatives of the public-private sphere, gaining exposure to a varied mix of working models from the area of biomedicine\u201d. She explains that the aim of the mission was to experience how the US biotechnology ecosystem works on the ground, and to better understand the issues of financing, working models, technology transfer and intellectual property.<\/p>\n

Accordingly, Palomo stresses that the mission not only benefited the participating delegates in terms of learning about the Massachusetts biotechnology cluster, but that it also allowed them to visualize practices and new forms of cooperation which can be replicated in Chile. \u201cFor example, the team learned about different capabilities and services, and came to realize that we in Chile are not so far off the Boston experience in terms of co-working. One example of this is the initiative led by Santiago LabSpace\u201d, she notes.<\/p>\n

The executive director of LabSpace, Ignacio Brescia, was one of the participating delegates on the AmCham Chile mission. During his time in the United States, he was able to gauge the structure of the biotechnology sphere in the country. He explains that, \u201cit was particularly interesting to see that everything happens on a centralized basis.\u00a0 MIT, Pfizer, Novartis, Janssen, universities, companies, research centers, investors\u2026 they are all in the same place, which greatly streamlines the processes. In fact, a scientist can just phone an investor to arrange a meeting in the Starbucks across the street, and in five minutes time they\u2019ll be talking about business. It\u2019s a \u2018let\u2019s just do it\u2019 attitude, in contrast to the way things work here (in Chile)\u201d.<\/p>\n

 <\/p>\n

\"yyukyuklyuklujlhju\"<\/p>\n

\u201cChile has scientists and entrepreneurs with great problem-solving abilities, and we want to maximize their extensive knowledge by trying to facilitate their path to developing new technology\u201d, says Pablo Zamora, scientific director at UC Davis Chile. This approach means that R2B Catalyst will have two types of infrastructure: UC Davis LabSpace laboratories in Providencia, in Santiago, for developing cellular, molecular and microbial biology; and Patagonia LabSpace in Puerto Montt, for the process of scaling or developing prototypes. In addition, the benefitting start-ups will gain access to all the knowledge and networks of the University of California, thereby enhancing their chances of successfully reaching the market.<\/p>\n

\u201cChile has excellent opportunities in the biotechnology field. However, until there is a vision which outlines the desire to be at the forefront of innovation development, we will simply be a fund-raising vehicle, and these technologies will just move on to other places for their production improvement\u201d, says Zamora.<\/p>\n

\"yyrtyrtyrt\"<\/p>\n

Biotechnology has taken great strides over the last decade. However, interested parties must wait for the publication, in 2016, of the road map being devised by Corfo to judge the potential of the industry: an industry which, despite generating an increasing number of projects, still requires additional resources and greater numbers of researchers dedicated to the development of the sector in Chile.[:]<\/p>\n","protected":false},"excerpt":{"rendered":"

[:es]Desde Corfo est\u00e1n impulsando la creaci\u00f3n de una Plataforma que d\u00e9 un norte estrat\u00e9gico al sector y agrupe de forma ordenada todas las iniciativas que hoy se est\u00e1n llevando a cabo de forma aislada. Por Alejandra Maturana\u00a0 \u201cNo s\u00f3lo queremos desarrollar con la biotecnolog\u00eda nuestras industrias basadas en recursos naturales, sino que tambi\u00e9n crear industrias […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"template":"","news_tax":[],"user_type":[],"class_list":["post-9479","news","type-news","status-publish","hentry"],"acf":[],"yoast_head":"\n[:es]Industria biotecnol\u00f3gica toma forma en Chile[:en]Biotechnology industry takes shape in Chile[:] - AmCham Chile<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"[:es]Industria biotecnol\u00f3gica toma forma en Chile[:en]Biotechnology industry takes shape in Chile[:] - AmCham Chile\" \/>\n<meta property=\"og:description\" content=\"[:es]Desde Corfo est\u00e1n impulsando la creaci\u00f3n de una Plataforma que d\u00e9 un norte estrat\u00e9gico al sector y agrupe de forma ordenada todas las iniciativas que hoy se est\u00e1n llevando a cabo de forma aislada. Por Alejandra Maturana\u00a0 \u201cNo s\u00f3lo queremos desarrollar con la biotecnolog\u00eda nuestras industrias basadas en recursos naturales, sino que tambi\u00e9n crear industrias […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/\" \/>\n<meta property=\"og:site_name\" content=\"AmCham Chile\" \/>\n<meta property=\"article:modified_time\" content=\"2015-12-11T20:07:27+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/amchamchile.cl\/wp-content\/uploads\/2015\/12\/777777777777.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/\",\"url\":\"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/\",\"name\":\"[:es]Industria biotecnol\u00f3gica toma forma en Chile[:en]Biotechnology industry takes shape in Chile[:] - AmCham Chile\",\"isPartOf\":{\"@id\":\"https:\/\/amchamchile.cl\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/amchamchile.cl\/wp-content\/uploads\/2015\/12\/777777777777.jpg\",\"datePublished\":\"2015-12-11T20:07:03+00:00\",\"dateModified\":\"2015-12-11T20:07:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/#primaryimage\",\"url\":\"http:\/\/amchamchile.cl\/wp-content\/uploads\/2015\/12\/777777777777.jpg\",\"contentUrl\":\"http:\/\/amchamchile.cl\/wp-content\/uploads\/2015\/12\/777777777777.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/amchamchile.cl\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"[:es]Industria biotecnol\u00f3gica toma forma en Chile[:en]Biotechnology industry takes shape in Chile[:]\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/amchamchile.cl\/#website\",\"url\":\"https:\/\/amchamchile.cl\/\",\"name\":\"AmCham Chile\",\"description\":\"C\u00e1mara Chilena Norteamericana de Comercio\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/amchamchile.cl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"[:es]Industria biotecnol\u00f3gica toma forma en Chile[:en]Biotechnology industry takes shape in Chile[:] - AmCham Chile","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/","og_locale":"en_US","og_type":"article","og_title":"[:es]Industria biotecnol\u00f3gica toma forma en Chile[:en]Biotechnology industry takes shape in Chile[:] - AmCham Chile","og_description":"[:es]Desde Corfo est\u00e1n impulsando la creaci\u00f3n de una Plataforma que d\u00e9 un norte estrat\u00e9gico al sector y agrupe de forma ordenada todas las iniciativas que hoy se est\u00e1n llevando a cabo de forma aislada. Por Alejandra Maturana\u00a0 \u201cNo s\u00f3lo queremos desarrollar con la biotecnolog\u00eda nuestras industrias basadas en recursos naturales, sino que tambi\u00e9n crear industrias […]","og_url":"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/","og_site_name":"AmCham Chile","article_modified_time":"2015-12-11T20:07:27+00:00","og_image":[{"url":"http:\/\/amchamchile.cl\/wp-content\/uploads\/2015\/12\/777777777777.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/","url":"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/","name":"[:es]Industria biotecnol\u00f3gica toma forma en Chile[:en]Biotechnology industry takes shape in Chile[:] - AmCham Chile","isPartOf":{"@id":"https:\/\/amchamchile.cl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/#primaryimage"},"image":{"@id":"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/#primaryimage"},"thumbnailUrl":"http:\/\/amchamchile.cl\/wp-content\/uploads\/2015\/12\/777777777777.jpg","datePublished":"2015-12-11T20:07:03+00:00","dateModified":"2015-12-11T20:07:27+00:00","breadcrumb":{"@id":"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/#primaryimage","url":"http:\/\/amchamchile.cl\/wp-content\/uploads\/2015\/12\/777777777777.jpg","contentUrl":"http:\/\/amchamchile.cl\/wp-content\/uploads\/2015\/12\/777777777777.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/amchamchile.cl\/noticia\/industria-biotecnologica-toma-forma-en-chile\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/amchamchile.cl\/en\/"},{"@type":"ListItem","position":2,"name":"[:es]Industria biotecnol\u00f3gica toma forma en Chile[:en]Biotechnology industry takes shape in Chile[:]"}]},{"@type":"WebSite","@id":"https:\/\/amchamchile.cl\/#website","url":"https:\/\/amchamchile.cl\/","name":"AmCham Chile","description":"C\u00e1mara Chilena Norteamericana de Comercio","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/amchamchile.cl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/news\/9479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/news\/9479\/revisions"}],"wp:attachment":[{"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/media?parent=9479"}],"wp:term":[{"taxonomy":"news_tax","embeddable":true,"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/news_tax?post=9479"},{"taxonomy":"user_type","embeddable":true,"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/user_type?post=9479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}